Synthesis of pH ‐sensitive grafted psyllium: Encapsulation of quercetin for colon cancer treatment

2021 ◽  
pp. 51552
Author(s):  
Deepak Kumar ◽  
Arti Gautam ◽  
Patit Paban Kundu
1999 ◽  
Vol 23 (5) ◽  
pp. 428-434 ◽  
Author(s):  
Sarah E. Tropman ◽  
Theresa Hatzell ◽  
Electra Paskett ◽  
Thomas Ricketts ◽  
M. robert Cooper ◽  
...  

2020 ◽  
Vol 231 (4) ◽  
pp. S55-S56
Author(s):  
Scarlett B. Hao ◽  
Rebecca A. Snyder ◽  
William Irish ◽  
Alexander A. Parikh

2018 ◽  
Vol 73 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Louise Hayes ◽  
Lynne Forrest ◽  
Jean Adams ◽  
Mira Hidajat ◽  
Yoav Ben-Shlomo ◽  
...  

BackgroundOlder people experience poorer outcomes from colon cancer. We examined if treatment for colon cancer was related to age and if inequalities changed over time.MethodsData from the UK population-based Northern and Yorkshire Cancer Registry on 31 910 incident colon cancers (ICD10 C18) diagnosed between 1999–2010 were obtained. Likelihood of receipt of: (1) cancer-directed surgery, (2) chemotherapy in surgical patients, (3) chemotherapy in non-surgical patients by age, adjusting for sex, area deprivation, cancer stage, comorbidity and period of diagnosis, was examined.ResultsAge-related inequalities in treatment exist after adjustment for confounding factors. Patients aged 60– 69, 70–79 and 80+ years were significantly less likely to receive surgery than those aged <60 years (multivariable ORs (95% CI) 0.84(0.74 to 0.95), 0.54(0.48 to 0.61) and 0.19(0.17 to 0.21), respectively). Age-related differences in receipt of surgery and adjuvant chemotherapy (but not chemotherapy in non-surgical patients) narrowed over time for the ’younger old’ (aged <80 years) but did not diminish for the oldest patients.ConclusionsAge inequality in treatment of colon cancer remains after adjustment for confounders, suggesting age remains a major factor in treatment decisions. Research is needed to better understand the cancer treatment decision-making process, and how to influence this, for older patients.


2019 ◽  
Vol 175 ◽  
pp. 477-486 ◽  
Author(s):  
Chang-Ming Liu ◽  
Guang-Bing Chen ◽  
Hui-Hong Chen ◽  
Jia-Bin Zhang ◽  
Hui-Zhang Li ◽  
...  

2017 ◽  
Vol 32 (3) ◽  
pp. 571-579 ◽  
Author(s):  
Nicole Ernstmann ◽  
Markus Wirtz ◽  
Anika Nitzsche ◽  
Sophie E. Gross ◽  
Lena Ansmann ◽  
...  

2021 ◽  
Vol 22 ◽  
Author(s):  
Vaidevi Sethuraman ◽  
Kumar Janakiraman ◽  
Venkateshwaran Krishnaswami ◽  
Ruckmani Kandasamy

Abstract: Stimuli responsive nanocarriers are gaining much attention due to its versatile multifunctional activities including disease diagnosis and treatment. Recently, clinical applications of nano drug delivery systems for cancer treatment make a considerable challenge due to its limited cellular uptake, low bioavailability, poor targetability, stability issues, and unfavourable pharmacokinetics. To overcome these issues researchers are focussing on stimuli responsive systems. Nano carriers elicit its role through endogenous (pH, temperature, enzyme and redox) or exogenous (temperature, light, magnetic field, ultrasound) stimulus. These systems were designed to overcome the shortcomings such as non-specificity and toxicity associated with the conventional drug delivery systems. The pH variation between healthy cells and tumor microenvironment creates a platform towards the generation of pH sensitive nano delivery systems. Herein, we propose to present an overview of various internal and external stimuli responsive behavior based drug delivery systems. Herein the present review will focus specifically on the significance of various pH- responsive nanomaterials such as polymeric nanoparticles, nano micelles, inorganic based pH sensitive drug delivery carriers such as calcium phosphate nanoparticles, and carbon dots in cancer treatment. Moreover, this review elaborates the recent findings on pH based stimuli responsive drug delivery system with special emphasis towards our reported stimuli responsive systems for cancer treatment.


Sign in / Sign up

Export Citation Format

Share Document